Binding Site will unveil Optilite at the MEDLAB Exhibition in Dubai, hosting product demonstrations for customers throughout the event. The company has spent more than four years developing Optilite in response to customer demand and the results are truly outstanding.
Charles de Rohan, CEO from Binding Site commented “We wanted to bring simplicity to complex analytical processes. The result is Optilite, the latest innovation in special protein testing, which offers laboratories reliable results without compromising speed and efficiency.”
As well as the Freelite®, Hevylite® and subclass assays, Optilite offers a comprehensive menu for special protein analysis of 40 CE marked assays. Freelite is the only assay recommended by both national and international guidelines including the International Myeloma Working Group Guidelines for diagnosis and monitoring of B cell dyscrasias, including Multiple Myeloma.